NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Bioquark, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health Products - The common mosquito, while being responsible for up to a million human deaths each year, may paradoxically also hold biochemical secrets to cure diseases that effect hundreds of millions of people around the globe - Bioquark.com
Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health Products

 

NewswireToday - /newswire/ - Philadelphia, PA, United States, 2019/01/10 - The common mosquito, while being responsible for up to a million human deaths each year, may paradoxically also hold biochemical secrets to cure diseases that effect hundreds of millions of people around the globe - Bioquark.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bioquark, Inc., an innovative life sciences company focused biotherapeutic development for human regeneration and disease reversion, and Ectocrine Technologies, LLC, a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, of have announced a collaboration to focus on developing novel bio-products for human health and wellness.

"We are very excited about this collaboration with Ectocrine Technologies," said Ira S. Pastor, CEO, Bioquark Inc. "The synergy of our approaches in studying evolutionarily perfected arrays of metabolites from the natural world, can lead to the development of novel therapeutics for a range of chronic diseases responsible for human degeneration and suffering. And nature’s ectocrine systems (the “Ectocrinome”) represents a completely un-tapped reservoir."

Nature’s ectocrine systems (or “Ectocrinome”, in similar model to the Microbiome), form an interlaced network across species, providing a range of beneficial bio-active effects. The saliva of mosquitos, as example, has been shown to contain novel neuro-peptides, anti-inflammatory molecules, anti-coagulants, pain killers, as well as a range of vasodilatory and immune-modulatory molecules. However, most of this knowledge has been completely obscured due to the extensive popular press focus on the mosquito being no more than a disease carrying pest.

Mosquito eradication programs, while offering a solution to the million deaths each year from mosquito born disease, ignore the critical immunopathological role that these creatures have played over hundreds of millions of years as they propagated their beneficial biochemical signals in invertebrates, fish, amphibians, reptiles, birds, mammals, and humans. While hygiene represents one of the most successful health / life extending interventions in history, many epidemiological studies show that, paradoxically, it may render humans at risk for the development of a range of chronic non-communicable diseases (NCDs), such as inflammatory bowel disease, multiple sclerosis, type I diabetes, asthma, and allergies. Furthermore, these pathological process might play a broad role in the pathogenesis of other NCDs associated with chronic inflammation such as atherosclerosis, type 2 diabetes, cancer, and neurodegenerative disorders.

"We look forward to working closely with Bioquark Inc. on this exciting initiative," said Dr. J. Santiago Mejia MD, CSO of Ectocrine Technologies, LLC. "The epidemiological evidence of low incidences of auto-immune diseases, inflammatory disorders, allergies, developmental diseases and certain cancers, in regions of high endemicity for arthropod-borne diseases, may interestingly point us towards previously ignored answers to combat these major causes of human degeneration and disease."

“We are not advocating for the suspension of the vector control programs used to eradicate malaria and other arthropod-borne diseases. Our concern is that these methods fail to discriminate infected from non-infected mosquitos, and as a result, residents of intervened areas are deprived of the potential health benefits derived from exposure to the salivary molecules delivered through the bite of healthy mosquitos,” said Mejia.

About Bioquark, Inc.

Bioquark, Inc. (bioquark.com) is an innovative life sciences company focused on the development of novel bio-products for human regeneration, disease reversion and rejuvenation, in relation to aging and age related pathologies.

About Ectocrine Technologies

Ectocrine Technologies, LLC is a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, as an essential source of molecules for human well-being and development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bioquark, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health Products

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Ira S. Pastor - Bioquark.com 
267-507-6155 pastor[.]bioquark.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bioquark, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bioquark, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  JobsWare.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)